MissionIR Articles
Category: CNS Pharmaceuticals Inc. CNSP
-
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Mines Investment-building Opportunity for Brain Tumor-Targeting Drug Candidate at Annual Conference
CNS Pharmaceuticals is a clinical-stage biotechnology company developing therapies to combat aggressive cancers of the brain and central nervous system The company will be applying for approval to launch Phase II trials in the first…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP), Sub-Licensee Partner Advancing Lead Drug Candidate in First-Ever Phase 1 and Phase 2 Clinical Trials
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, is advancing its leading drug candidate, Berubicin, to move…
Search Articles
Latest Articles
- Forward Industries Inc. (NASDAQ: FWDI) Executes the Company’s Solana Treasury Strategy to Build on a Successful 2026 Fiscal Q1
- MissionIRNewsBreaks – Olenox Industries (NASDAQ: OLOX) Launches 2026 Drilling Program, Targets 1,000 BOE per Day by Year-End
- Safe Pro Group Inc. (NASDAQ: SPAI) Secures Contract to Provide U.S. Government with AI Systems, Representing Significant Q1 2026 Revenue Growth
- HeartBeam Inc. (NASDAQ: BEAT) Upgraded to Buy as New Joseph Gunnar Report Raises Price Target on Commercialization Momentum
- MissionIRNewsBreaks – Wearable Devices Ltd. (NASDAQ: WLDS) to Debut Mudra Experience Studio at MWC Barcelona 2026